Search results

Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).

Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).

Accelerate therapeutic discovery and maximize ROI with our streamlined platform, fully integrated across your entire portfolio. Use digital and decentralized trials to scale your pipeline beyond what's possible with traditional clinical trials.

Join leading clinical experts as they discuss and debunk the top 5 myths about eCOA in 2025, separating fact from fiction to help clinical operations, procurement, and data management teams make smarter, faster decisions.

Explore the prevalent challenges encountered in eCOA clinical trials, from technical issues and patient adherence to data security and regulatory adherence, and discover strategies for mitigation.

With MarketsandMarkets projecting the global electronic Clinical Outcome Assessments (eCOA) solutions market to grow at compound annual growth rate (CAGR) of 16.1% each year until 2030, it’s clear the eCOA has made its impact within the clinical research landscape. Yet despite growing adoption, electronic Clinical Outcome Assessments (eCOA) are still surrounded by misconceptions that hinder their full potential. From concerns about patient usability to assumptions about cost and implementation timelines, these myths can create hesitation among sponsors and research teams alike.Thus, we’re here to cut through the noise and set the record straight with a summary of a recent webinar featuring speakers from Transcelerate and Medable.

Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).

Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).

Gain a quick overview of what top trends and topics dominated DIA 2023.

With the 14th annual DPHARM® wrapping up, we talked to our peers across the industry to find out what the big themes and takeaways were from this year’s conference.

Discover how Medable helped digitize and standardize a client's participant pain body maps for a diabetic polyneuropathy trial.

Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).

Regain control and stay competitive with Medable Studio—your all-in-one platform to build and launch protocol-fit digital solutions for your customers.

See why many of the top pharma are focused on building the "next model" of clinical trial conduct using foundational platforms.

Medable's CRO Partner Program equips you with advanced GenAI and automation tools to accelerate clinical trial builds, streamline data collection, and offer flexible service tiers tailored to your operational needs. Empower your studies and win more business.

Learn how Medable's eCOA (electronic clinical outcome assessment) solution was able to deliver >90% adherence and scalability for a top pharmaceutical weight management clinical trial.

Along with some of the best companies in the world, Medable is proud to join CancerX as a founding member. This alliance is co-hosted by the Moffitt Cancer Center and the Digital Medicine Society (DiMe), alongside the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH).

Contact Medable for a demo and to learn more about DCT certification, careers, and support. Medable, per Everest Group Peak matrix, is the top decentralized clinical trial company.

Discover how Medable is revolutionizing clinical trials with faster enrollment, more control and transparency, and patient-first solutions. Learn how we’re expanding access to life-changing treatments globally, driving innovation, and transforming operations for better outcomes in clinical research.

A top 10 pharmaceutical company looked to Medable to streamline participant burden and enhance site and team experience in oncology trials, while establishing a scalable template for future trials in oncology and other areas.

See how customers have had success with Medable, our trial platform, and our teams.

Streamline your clinical trial and generate high-quality data with a #1 rated, easy-to-use platform, offered in over 60 countries and 120 languages. Book a demo to learn more.

Learn how top pharma are using novel innovations to drive greater speed, scale, and access in clinical research than ever before in this webinar hosted by Musaddiq Khan, Vice President of DCT Solutions at Medable.

A top-3 contract research organization (CRO) and a top-10 pharmaceutical company partnered with Medable to help accelerate the speed, scale, and standardization of their eCOA trials.The two organizations had been hampered by lengthy configuration timelines, inconsistent designs across studies, and siloed processes between sponsors and their CRO partners.By centralizing the sponsor’s preferred instruments and configurations into a reusable digital library, Medable enabled the CRO to rapidly accelerate its portfolio development and initiate new studies without starting them “from scratch.”‍

Join Medable's Mohammed Ali, Chief Domain Expert and Shubha Govil, SVP of Product Management,Platform to hear how top pharma teams have adopted digital technology across a platform to reduce costs and accelerate time to market.

Medable worked with a top 5 pharma company to increase the safety of patients as anti-cancer treatments may cause pulmonary toxicity, ranging from asymptomatic radiological changes to respiratory failure, and is considered a common side effect.

This summary looks at DCT patient and caregiver preferences regarding eConsent, telehealth, wearables, and other digital technologies in the area of oncology. There are differences noted between age, gender, and specific types of cancers.

In this webinar, learn how top pharma are using novel innovations to drive greater speed, scale, and access in clinical research than ever before in this webinar hosted by Musaddiq Khan, Vice President of DCT Solutions at Medable.

Learn how we can help you navigate the complexities of clinical operations so that you can meet your study's milestones faster and easier.

When talking to customers conducting their first multi-country trial, we sometimes liken clinical trials to spider webs. Just as a garden spider’s web differs from a black widow’s, clinical trials follow unique patterns in every region. Each country comes with its own set of rules, ethical standards, approval processes, and data privacy laws. Cultural factors also play a crucial role in how patients are recruited and understand Clinical trials, requiring sensitive communication and a deep respect for participants’ needs.In Japan, these regulatory and cultural intricacies form a complex ‘web,’ with anchor points and structural requirements that, when understood and implemented correctly, create a framework for success. However, conducting Clinical trials in Japan has historically posed challenges for Sponsors and Contract Research Organizations (CROs). When we first entered the region, one Sponsor consistently cited issues with eCOA solutions and site and patient support, not fully adapting to Japan’s unique requirements. This feedback, combined with our own experiences on the ground, revealed a clear need for improvement.Today, we can proudly say that the solutions we put in place have transformed Japan’s Clinical trial landscape, and what was once a challenge has now become the “gold standard” for supporting Clinical trials in the region.

Since its inception, Medable has prioritized scientific integrity and rigor around various aspects of clinical trials. As part of its science team, Cindy Howry, VP of eCOA Science, plays a crucial role in ensuring that Medable’s clinical trial platform accurately captures electronic Clinical Outcome Assessments (eCOAs). Hired in 2023, Howry’s chief purpose at Medable is to ensure that the health economics and outcomes research (HEOR) science behind our technology is based on best practices and regulatory guidance.

A top-10 global pharmaceutical company aimed to address eCOA adherence and patient enrollment challenges faced by clinical trial sites and participants in Japan. Recognizing Japan’s distinct regulatory, cultural, and logistical landscape, the company partnered with Medable to develop an initiative to enhance the region’s patient and site experience.

A top, global clinical research organization (CRO) partnered with Medable to transform its approach to clinical trial building. Recognizing the inefficiencies in traditional build processes that often “take weeks,” the client leveraged Medable’s Studio platform with its latest AI capabilities to dramatically accelerate timelines, enhance transparency, and improve quality. ‍‍

One of the most common questions we’re asked about digital informed consent/eConsent is: What does the ICF amendment or revision process look like within a digital platform and is this harder or easier than traditional paper-based approaches? Get the answer here.

See how Medable was able to increase study startup speed for one customer by 50%.

See how Medable helped one customer achieve their fastest enrollment ever.

The partnership between Medable, U.S. Renal Care, and the top ten pharmaceutical sponsor exemplifies the transformative power of Medable’s Total Consent solution in clinical trials. By overcoming common misconceptions around participant age, cost, and complexity, Medable’s platform proved to be a flexible, fast, and efficient solution for the elderly renal care population. U.S. Renal Care sought to use Medable’s Total Consent (Medable’s eConsent solution) for an investigator-initiated trial. The phase 4 trial, which was funded by a top 10 pharmaceutical company, sought to enroll elderly participants suffering from Anemia ESKD (End Stage Kidney Disease) across 476 site users. The trial would be managed by three central principal investigators (PIs).

A top-10 global pharmaceutical company partnered with Medable for their pivotal Phase III diabetes study in the highly competitive market. Recognizing the inefficiencies in traditional study delivery and closeout processes, the company leveraged Medable’s expertise to accelerate timelines, enhance operational efficiency, and achieve a faster time to market for this high-profile therapy.

See how a pharmaceutical company used data gathered during the informed consent process to pre-populate their site's systems, as well as their own.